메뉴 건너뛰기




Volumn 12, Issue 1, 2015, Pages 24-32

Incretin-Related Drug Therapy in Heart Failure

Author keywords

Diabetes; DPP 4; GLP 1; Heart failure; Incretins; Left ventricular dysfunction; Myocardial metabolism; Obesity; Reperfusion injury

Indexed keywords

ALBIGLUTIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DULAGLUTIDE; EXENDIN 4; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; INCRETIN; INSULIN; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; POTASSIUM; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN; CARDIOVASCULAR AGENT;

EID: 84939814711     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-014-0232-6     Document Type: Review
Times cited : (10)

References (59)
  • 1
    • 84872091789 scopus 로고    scopus 로고
    • Heart disease and stroke statistics - 2013 update: a report from the American Heart Association
    • PID: 2323983
    • Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics - 2013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6.
    • (2013) Circulation , vol.127 , Issue.1 , pp. e6
    • Go, A.S.1    Mozaffarian, D.2    Roger, V.L.3    Benjamin, E.J.4    Berry, J.D.5    Borden, W.B.6
  • 2
    • 34547590901 scopus 로고    scopus 로고
    • Metabolic mechanisms in heart failure
    • COI: 1:CAS:528:DC%2BD2sXnslKksLs%3D, PID: 1764659
    • Ashrafian H, Frenneaux MP, Opie LH. Metabolic mechanisms in heart failure. Circulation. 2007;116(4):434–48.
    • (2007) Circulation , vol.116 , Issue.4 , pp. 434-448
    • Ashrafian, H.1    Frenneaux, M.P.2    Opie, L.H.3
  • 3
    • 77049132699 scopus 로고
    • The metabolism of the human heart in vivo
    • COI: 1:CAS:528:DyaG2cXhvFWlsA%3D%3D, PID: 1308514
    • Bing RJ. The metabolism of the human heart in vivo. J Mt Sinai Hosp N Y. 1953;20(2):100–17.
    • (1953) J Mt Sinai Hosp N Y , vol.20 , Issue.2 , pp. 100-117
    • Bing, R.J.1
  • 4
    • 0141917504 scopus 로고    scopus 로고
    • Prognostic benefits of heart rate reduction in cardiovascular disease
    • Ferrari R. Prognostic benefits of heart rate reduction in cardiovascular disease. Eur Heart J Suppl. 2003;5:G10–4.
    • (2003) Eur Heart J Suppl , vol.5 , pp. G10-G14
    • Ferrari, R.1
  • 5
    • 3342967512 scopus 로고    scopus 로고
    • Is the failing heart energy starved? on using chemical energy to support cardiac function
    • COI: 1:CAS:528:DC%2BD2cXls1Gqtbw%3D, PID: 1527186
    • Ingwall JS, Weiss RG. Is the failing heart energy starved? on using chemical energy to support cardiac function. Circ Res. 2004;95(2):135–45.
    • (2004) Circ Res , vol.95 , Issue.2 , pp. 135-145
    • Ingwall, J.S.1    Weiss, R.G.2
  • 6
    • 33947239659 scopus 로고    scopus 로고
    • The failing heart—an engine out of fuel
    • PID: 1736099
    • Neubauer S. The failing heart—an engine out of fuel. N Engl J Med. 2007;356(11):1140–51.
    • (2007) N Engl J Med , vol.356 , Issue.11 , pp. 1140-1151
    • Neubauer, S.1
  • 7
    • 21244492310 scopus 로고    scopus 로고
    • Myocardial substrate metabolism in the normal and failing heart
    • COI: 1:CAS:528:DC%2BD2MXmsFylsr0%3D, PID: 1598780
    • Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev. 2005;85(3):1093–129.
    • (2005) Physiol Rev , vol.85 , Issue.3 , pp. 1093-1129
    • Stanley, W.C.1    Recchia, F.A.2    Lopaschuk, G.D.3
  • 8
    • 0036285606 scopus 로고    scopus 로고
    • Energy metabolism in the normal and failing heart: potential for therapeutic interventions
    • COI: 1:CAS:528:DC%2BD38XkvVWqtbc%3D, PID: 1198863
    • Stanley WC, Chandler MP. Energy metabolism in the normal and failing heart: potential for therapeutic interventions. Heart Fail Rev. 2002;7(2):115–30.
    • (2002) Heart Fail Rev , vol.7 , Issue.2 , pp. 115-130
    • Stanley, W.C.1    Chandler, M.P.2
  • 9
    • 0035136262 scopus 로고    scopus 로고
    • An evaluation of myocardial fatty acid and glucose uptake using PET with [18 F]fluoro-6-thia-heptadecanoic acid and [18 F]FDG in patients with congestive heart failure
    • COI: 1:CAS:528:DC%2BD3MXhtF2nsbY%3D, PID: 1119798
    • Taylor M, Wallhaus TR, Degrado TR, Russell DC, Stanko P, Nickles RJ, et al. An evaluation of myocardial fatty acid and glucose uptake using PET with [18 F]fluoro-6-thia-heptadecanoic acid and [18 F]FDG in patients with congestive heart failure. J Nucl Med. 2001;42(1):55–62.
    • (2001) J Nucl Med , vol.42 , Issue.1 , pp. 55-62
    • Taylor, M.1    Wallhaus, T.R.2    Degrado, T.R.3    Russell, D.C.4    Stanko, P.5    Nickles, R.J.6
  • 10
    • 0028144326 scopus 로고
    • Total-body and myocardial substrate oxidation in congestive heart failure
    • COI: 1:STN:280:DyaK2c7ms1KnsQ%3D%3D, PID: 812129
    • Paolisso G, Gambardella A, Galzerano D, D'Amore A, Rubino P, Verza M, et al. Total-body and myocardial substrate oxidation in congestive heart failure. Metab Clin Exp. 1994;43(2):174–9.
    • (1994) Metab Clin Exp , vol.43 , Issue.2 , pp. 174-179
    • Paolisso, G.1    Gambardella, A.2    Galzerano, D.3    D'Amore, A.4    Rubino, P.5    Verza, M.6
  • 11
    • 3342886026 scopus 로고    scopus 로고
    • The incidence of congestive heart failure in type 2 diabetes: an update
    • PID: 1527741
    • Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care. 2004;27(8):1879–84.
    • (2004) Diabetes Care , vol.27 , Issue.8 , pp. 1879-1884
    • Nichols, G.A.1    Gullion, C.M.2    Koro, C.E.3    Ephross, S.A.4    Brown, J.B.5
  • 12
    • 0030751957 scopus 로고    scopus 로고
    • Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure
    • COI: 1:CAS:528:DyaK2sXlsFWrsbc%3D, PID: 924752
    • Swan JW, Anker SD, Walton C, Godsland IF, Clark AL, Leyva F, et al. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol. 1997;30(2):527–32.
    • (1997) J Am Coll Cardiol , vol.30 , Issue.2 , pp. 527-532
    • Swan, J.W.1    Anker, S.D.2    Walton, C.3    Godsland, I.F.4    Clark, A.L.5    Leyva, F.6
  • 13
    • 77956190021 scopus 로고    scopus 로고
    • Impaired glucose tolerance and insulin resistance in heart failure: underrecognized and undertreated?
    • COI: 1:CAS:528:DC%2BC3cXhtVymtbbL, PID: 2079760
    • Mamas MA, Deaton C, Rutter MK, Yuille M, Williams SG, Ray SG, et al. Impaired glucose tolerance and insulin resistance in heart failure: underrecognized and undertreated? J Card Fail. 2010;16(9):761–8.
    • (2010) J Card Fail , vol.16 , Issue.9 , pp. 761-768
    • Mamas, M.A.1    Deaton, C.2    Rutter, M.K.3    Yuille, M.4    Williams, S.G.5    Ray, S.G.6
  • 14
    • 0034095332 scopus 로고    scopus 로고
    • Myocardial substrate metabolism influences left ventricular energetics in vivo
    • COI: 1:CAS:528:DC%2BD3cXislSksrs%3D, PID: 1074973
    • Korvald C, Elvenes OP, Myrmel T. Myocardial substrate metabolism influences left ventricular energetics in vivo. Am J Physiol Heart Circ Physiol. 2000;278(4):H1345–51.
    • (2000) Am J Physiol Heart Circ Physiol , vol.278 , Issue.4 , pp. H1345-H1351
    • Korvald, C.1    Elvenes, O.P.2    Myrmel, T.3
  • 15
    • 18344394762 scopus 로고    scopus 로고
    • Glucose insulin potassium infusion improves systolic function in patients with chronic ischemic cardiomyopathy
    • COI: 1:CAS:528:DC%2BD38XhslWgu70%3D, PID: 1195904
    • Cottin Y, Lhuillier I, Gilson L, Zeller M, Bonnet C, Toulouse C, et al. Glucose insulin potassium infusion improves systolic function in patients with chronic ischemic cardiomyopathy. Eur J Heart Fail. 2002;4(2):181–4.
    • (2002) Eur J Heart Fail , vol.4 , Issue.2 , pp. 181-184
    • Cottin, Y.1    Lhuillier, I.2    Gilson, L.3    Zeller, M.4    Bonnet, C.5    Toulouse, C.6
  • 16
    • 54549095054 scopus 로고    scopus 로고
    • Effect of glucose-insulin-potassium in severe acute heart failure after brain death
    • COI: 1:CAS:528:DC%2BD1cXhtFCksbrJ, PID: 1876609
    • Nicolas-Robin A, Amour J, Ibanez-Esteve C, Coriat P, Riou B, Langeron O. Effect of glucose-insulin-potassium in severe acute heart failure after brain death. Crit Care Med. 2008;36(10):2740–5.
    • (2008) Crit Care Med , vol.36 , Issue.10 , pp. 2740-2745
    • Nicolas-Robin, A.1    Amour, J.2    Ibanez-Esteve, C.3    Coriat, P.4    Riou, B.5    Langeron, O.6
  • 17
    • 77954296979 scopus 로고    scopus 로고
    • A meta-analysis of glucose-insulin-potassium therapy for treatment of acute myocardial infarction
    • PID: 2063185
    • Mamas A, Mamas LNFF-O. A meta-analysis of glucose-insulin-potassium therapy for treatment of acute myocardial infarction. Exp Clin Cardiol. 2010;15(2):e20.
    • (2010) Exp Clin Cardiol , vol.15 , Issue.2 , pp. e20
    • Mamas, A.1    Mamas, L.N.F.F.-O.2
  • 18
    • 0342460492 scopus 로고    scopus 로고
    • Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia
    • COI: 1:STN:280:DyaK2szos1eksA%3D%3D, PID: 924422
    • Anker SD, Chua TP, Ponikowski P, Harrington D, Swan JW, Kox WJ, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation. 1997;96(2):526–34.
    • (1997) Circulation , vol.96 , Issue.2 , pp. 526-534
    • Anker, S.D.1    Chua, T.P.2    Ponikowski, P.3    Harrington, D.4    Swan, J.W.5    Kox, W.J.6
  • 19
    • 84878753499 scopus 로고    scopus 로고
    • Incretin dysfunction in type 2 diabetes: clinical impact and future perspectives
    • PID: 2364334
    • Ahrén B. Incretin dysfunction in type 2 diabetes: clinical impact and future perspectives. Diabetes Metab. 2013;39(3):195–201.
    • (2013) Diabetes Metab , vol.39 , Issue.3 , pp. 195-201
    • Ahrén, B.1
  • 20
    • 34248223285 scopus 로고    scopus 로고
    • Biology of incretins: GLP-1 and GIP
    • COI: 1:CAS:528:DC%2BD2sXmsVynsrY%3D, PID: 1749850
    • Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131–57.
    • (2007) Gastroenterology , vol.132 , Issue.6 , pp. 2131-2157
    • Baggio, L.L.1    Drucker, D.J.2
  • 21
    • 84898964381 scopus 로고    scopus 로고
    • GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?
    • COI: 1:CAS:528:DC%2BC2cXmslyjt74%3D, PID: 2449929
    • Brunton S. GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other? Int J Clin Pract. 2014;68(5):557–67.
    • (2014) Int J Clin Pract , vol.68 , Issue.5 , pp. 557-567
    • Brunton, S.1
  • 22
    • 84876063836 scopus 로고    scopus 로고
    • Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case–control study
    • COI: 1:CAS:528:DC%2BC3sXmt1ektr0%3
    • Singh S, Chang H-Y, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case–control study. JAMA Int Med. 2013;173(7):534–9.
    • (2013) JAMA Int Med , vol.173 , Issue.7 , pp. 534-539
    • Singh, S.1    Chang, H.-Y.2    Richards, T.M.3    Weiner, J.P.4    Clark, J.M.5    Segal, J.B.6
  • 23
    • 33646795007 scopus 로고    scopus 로고
    • Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts
    • COI: 1:CAS:528:DC%2BD28Xlt1eqtL8%3D, PID: 1648912
    • Zhao T, Parikh P, Bhashyam S, Bolukoglu H, Poornima I, Shen Y-T, et al. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther. 2006;317(3):1106–13.
    • (2006) J Pharmacol Exp Ther , vol.317 , Issue.3 , pp. 1106-1113
    • Zhao, T.1    Parikh, P.2    Bhashyam, S.3    Bolukoglu, H.4    Poornima, I.5    Shen, Y.-T.6
  • 24
    • 77955480007 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 increases myocardial glucose uptake via p38 MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy
    • Bhashyam S, Fields AV, Patterson B, Testani JM, Chen L, Shen YT, et al. Glucagon-like peptide-1 increases myocardial glucose uptake via p38 MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy. Circ: Heart Fail. 2010;3(4):512–21.
    • (2010) Circ: Heart Fail , vol.3 , Issue.4 , pp. 512-521
    • Bhashyam, S.1    Fields, A.V.2    Patterson, B.3    Testani, J.M.4    Chen, L.5    Shen, Y.T.6
  • 25
    • 12144260853 scopus 로고    scopus 로고
    • Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury
    • COI: 1:CAS:528:DC%2BD2MXhtVWju7k%3D, PID: 1561602
    • Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes. 2005;54(1):146–51.
    • (2005) Diabetes , vol.54 , Issue.1 , pp. 146-151
    • Bose, A.K.1    Mocanu, M.M.2    Carr, R.D.3    Brand, C.L.4    Yellon, D.M.5
  • 26
    • 0037629509 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 (7–36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium
    • COI: 1:CAS:528:DC%2BD3sXltF2ms78%3D, PID: 1286020
    • Kavianipour M, Ehlers MR, Malmberg K, Ronquist G, Ryden L, Wikström G, et al. Glucagon-like peptide-1 (7–36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium. Peptides. 2003;24(4):569–78.
    • (2003) Peptides , vol.24 , Issue.4 , pp. 569-578
    • Kavianipour, M.1    Ehlers, M.R.2    Malmberg, K.3    Ronquist, G.4    Ryden, L.5    Wikström, G.6
  • 27
    • 64649102619 scopus 로고    scopus 로고
    • GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice
    • COI: 1:CAS:528:DC%2BD1MXktleiu7o%3D, PID: 1915120
    • Noyan-Ashraf MH, Momen MA, Ban K, Sadi A-M, Zhou Y-Q, Riazi AM, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes. 2009;58(4):975–83.
    • (2009) Diabetes , vol.58 , Issue.4 , pp. 975-983
    • Noyan-Ashraf, M.H.1    Momen, M.A.2    Ban, K.3    Sadi, A.-M.4    Zhou, Y.-Q.5    Riazi, A.M.6
  • 28
    • 58949084130 scopus 로고    scopus 로고
    • Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury
    • COI: 1:CAS:528:DC%2BD1MXhsFOgtL4%3D, PID: 1919560
    • Timmers L, Henriques JPS, de Kleijn DPV, DeVries JH, Kemperman H, Steendijk P, et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol. 2009;53(6):501–10.
    • (2009) J Am Coll Cardiol , vol.53 , Issue.6 , pp. 501-510
    • Timmers, L.1    Henriques, J.P.S.2    de Kleijn, D.P.V.3    DeVries, J.H.4    Kemperman, H.5    Steendijk, P.6
  • 29
    • 11844269899 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines
    • COI: 1:CAS:528:DC%2BD2MXhtVWmtbY%3D, PID: 1535621
    • Nikolaidis LA, Doverspike A, Hentosz T, Zourelias L, Shen Y-T, Elahi D, et al. Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines. J Pharmacol Exp Ther. 2005;312(1):303–8.
    • (2005) J Pharmacol Exp Ther , vol.312 , Issue.1 , pp. 303-308
    • Nikolaidis, L.A.1    Doverspike, A.2    Hentosz, T.3    Zourelias, L.4    Shen, Y.-T.5    Elahi, D.6
  • 30
    • 84879120827 scopus 로고    scopus 로고
    • Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia-reperfusion injury
    • PID: 2228544
    • Chinda K, Palee S, Surinkaew S, Phornphutkul M, Chattipakorn S, Chattipakorn N. Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia-reperfusion injury. Int J Cardiol. 2013;167(2):451–7.
    • (2013) Int J Cardiol , vol.167 , Issue.2 , pp. 451-457
    • Chinda, K.1    Palee, S.2    Surinkaew, S.3    Phornphutkul, M.4    Chattipakorn, S.5    Chattipakorn, N.6
  • 31
    • 80053358548 scopus 로고    scopus 로고
    • Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure
    • COI: 1:CAS:528:DC%2BC3MXhs1Wjtb7I, PID: 2195556
    • Yin M, Silljé HHW, Meissner M, van Gilst WH, de Boer RA. Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure. Cardiovasc Diabetol. 2011;10:85.
    • (2011) Cardiovasc Diabetol , vol.10 , pp. 85
    • Yin, M.1    Silljé, H.H.W.2    Meissner, M.3    van Gilst, W.H.4    de Boer, R.A.5
  • 32
    • 1442311383 scopus 로고    scopus 로고
    • Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion
    • COI: 1:CAS:528:DC%2BD2cXhsFeisbY%3D, PID: 1498100
    • Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004;109(8):962–5.
    • (2004) Circulation , vol.109 , Issue.8 , pp. 962-965
    • Nikolaidis, L.A.1    Mankad, S.2    Sokos, G.G.3    Miske, G.4    Shah, A.5    Elahi, D.6
  • 33
    • 84860390563 scopus 로고    scopus 로고
    • A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans
    • COI: 1:CAS:528:DC%2BC3MXpsVGksb8%3
    • Read PA, Hoole SP, White PA, Khan FZ, O'Sullivan M, West NEJ, et al. A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans. Circ: Cardiovasc Interv. 2011;4(3):266–72.
    • (2011) Circ: Cardiovasc Interv , vol.4 , Issue.3 , pp. 266-272
    • Read, P.A.1    Hoole, S.P.2    White, P.A.3    Khan, F.Z.4    O'Sullivan, M.5    West, N.E.J.6
  • 34
    • 84857111888 scopus 로고    scopus 로고
    • Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease
    • COI: 1:CAS:528:DC%2BC38XltFKls7o%3D, PID: 21561896, A randomized crossover study of 14 patients with coronary artery disease and normal LV function awaiting revascularization. Participants underwent two dobutamine stress echocardiograms, one with an infusion of GLP-1 (7–36) amide and one with normal saline starting 30 min before the stress test and continuing for 30 min into recovery. At rest the infusion of GLP-1 did not affect LVEF - 62.3 ± 5.6 % (GLP-1) vs 62.6 ± 5.9 % (control); p = 0.74 – but at peak stress myocardial performance was augmented during GLP-1 infusion – LVEF 77.0 ± 4.4 % vs 70.8 ± 5.0 %; p < 0.0001. This demonstrates an important observation that GLP-1 may improve myocardial resilience during periods of ischemic stres
    • Read PA, Khan FZ, Dutka DP. Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease. Heart. 2012;98(5):408–13. A randomized crossover study of 14 patients with coronary artery disease and normal LV function awaiting revascularization. Participants underwent two dobutamine stress echocardiograms, one with an infusion of GLP-1 (7–36) amide and one with normal saline starting 30 min before the stress test and continuing for 30 min into recovery. At rest the infusion of GLP-1 did not affect LVEF - 62.3 ± 5.6 % (GLP-1) vs 62.6 ± 5.9 % (control); p = 0.74 – but at peak stress myocardial performance was augmented during GLP-1 infusion – LVEF 77.0 ± 4.4 % vs 70.8 ± 5.0 %; p < 0.0001. This demonstrates an important observation that GLP-1 may improve myocardial resilience during periods of ischemic stress.
    • (2012) Heart , vol.98 , Issue.5 , pp. 408-413
    • Read, P.A.1    Khan, F.Z.2    Dutka, D.P.3
  • 35
    • 77951934948 scopus 로고    scopus 로고
    • DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease
    • Read PA, Khan FZ, Heck PM, Hoole SP, Dutka DP. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ: Cardiovasc Imaging. 2010;3(2):195–201.
    • (2010) Circ: Cardiovasc Imaging , vol.3 , Issue.2 , pp. 195-201
    • Read, P.A.1    Khan, F.Z.2    Heck, P.M.3    Hoole, S.P.4    Dutka, D.P.5
  • 36
    • 4344605042 scopus 로고    scopus 로고
    • Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy
    • COI: 1:CAS:528:DC%2BD2cXms1OgtLw%3D, PID: 1531394
    • Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, Zourelias L, et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation. 2004;110(8):955–61.
    • (2004) Circulation , vol.110 , Issue.8 , pp. 955-961
    • Nikolaidis, L.A.1    Elahi, D.2    Hentosz, T.3    Doverspike, A.4    Huerbin, R.5    Zourelias, L.6
  • 37
    • 58949102483 scopus 로고    scopus 로고
    • Chronic Glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat
    • COI: 1:CAS:528:DC%2BD1cXhtV2jsrz
    • Poornima I, Brown SB, Bhashyam S, Parikh P, Bolukoglu H, Shannon RP. Chronic Glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat. Circ: Heart Fail. 2008;1(3):153–60.
    • (2008) Circ: Heart Fail , vol.1 , Issue.3 , pp. 153-160
    • Poornima, I.1    Brown, S.B.2    Bhashyam, S.3    Parikh, P.4    Bolukoglu, H.5    Shannon, R.P.6
  • 38
    • 79951979265 scopus 로고    scopus 로고
    • Exenatide improves glucose homeostasis and prolongs survival in a murine model of dilated cardiomyopathy
    • COI: 1:CAS:528:DC%2BC3MXisl2jurc%3D, PID: 2135920
    • Vyas AK, Yang K-C, Woo D, Tzekov A, Kovacs A, Jay PY, et al. Exenatide improves glucose homeostasis and prolongs survival in a murine model of dilated cardiomyopathy. PLoS ONE. 2011;6(2):e17178.
    • (2011) PLoS ONE , vol.6 , Issue.2 , pp. e17178
    • Vyas, A.K.1    Yang, K.-C.2    Woo, D.3    Tzekov, A.4    Kovacs, A.5    Jay, P.Y.6
  • 39
    • 78149493266 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure
    • PID: 2108095
    • Liu Q, Anderson C, Broyde A, Polizzi C, Fernandez R, Baron A, et al. Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure. Cardiovasc Diabetol. 2010;9(1):76.
    • (2010) Cardiovasc Diabetol , vol.9 , Issue.1 , pp. 76
    • Liu, Q.1    Anderson, C.2    Broyde, A.3    Polizzi, C.4    Fernandez, R.5    Baron, A.6
  • 40
    • 33644682164 scopus 로고    scopus 로고
    • Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure
    • Thrainsdottir I, Malmberg K, Olsson A, Gutniak M, Ryden L. Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure. Diabetes Vasc Dis Res. 2004;1(1):40.
    • (2004) Diabetes Vasc Dis Res , vol.1 , Issue.1 , pp. 40
    • Thrainsdottir, I.1    Malmberg, K.2    Olsson, A.3    Gutniak, M.4    Ryden, L.5
  • 41
    • 33845293219 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure
    • COI: 1:CAS:528:DC%2BD28XhtlaqsrzK, PID: 1717423
    • Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail. 2006;12(9):694–9.
    • (2006) J Card Fail , vol.12 , Issue.9 , pp. 694-699
    • Sokos, G.G.1    Nikolaidis, L.A.2    Mankad, S.3    Elahi, D.4    Shannon, R.P.5
  • 42
    • 77749273703 scopus 로고    scopus 로고
    • Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure
    • COI: 1:CAS:528:DC%2BC3cXjsFGnsLo%3D, PID: 20081109, A well-conducted human pilot study using a randomized double-blind crossover design to study 48 hours of GLP-1 infusion in 20 NYHA II-III subjects without diabetes. The findings were notable for no significant change in cardiac index, LVEF, diastolic function, exercise capacity, regional myocardial contractile function, or BNP with GLP-1 treatment. This study also raised concerns regarding safety in the HF population, because GLP-1 infusion increased circulating insulin levels and reduced plasma glucose levels and resulted in hypoglycemia in eight patient
    • Halbirk M, Nørrelund H, Møller N, Holst JJ, Schmitz O, Nielsen R, et al. Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure. Am J Physiol Heart Circ Physiol. 2010;298(3):H1096–102. A well-conducted human pilot study using a randomized double-blind crossover design to study 48 hours of GLP-1 infusion in 20 NYHA II-III subjects without diabetes. The findings were notable for no significant change in cardiac index, LVEF, diastolic function, exercise capacity, regional myocardial contractile function, or BNP with GLP-1 treatment. This study also raised concerns regarding safety in the HF population, because GLP-1 infusion increased circulating insulin levels and reduced plasma glucose levels and resulted in hypoglycemia in eight patients.
    • (2010) Am J Physiol Heart Circ Physiol , vol.298 , Issue.3 , pp. H1096-H1102
    • Halbirk, M.1    Nørrelund, H.2    Møller, N.3    Holst, J.J.4    Schmitz, O.5    Nielsen, R.6
  • 43
    • 28144441354 scopus 로고    scopus 로고
    • Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy
    • COI: 1:CAS:528:DC%2BD28XlslGnug%3D%3D, PID: 1602457
    • Nikolaidis LA, Elahi D, Shen Y-T, Shannon RP. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol. 2005;289(6):H2401–8.
    • (2005) Am J Physiol Heart Circ Physiol , vol.289 , Issue.6 , pp. H2401-H2408
    • Nikolaidis, L.A.1    Elahi, D.2    Shen, Y.-T.3    Shannon, R.P.4
  • 44
    • 43249089631 scopus 로고    scopus 로고
    • Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways
    • COI: 1:CAS:528:DC%2BD1cXltFyltrY%3D, PID: 1842713
    • Ban K, Noyan-Ashraf MH, Hoefer J, Bolz S-S, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation. 2008;117(18):2340–50.
    • (2008) Circulation , vol.117 , Issue.18 , pp. 2340-2350
    • Ban, K.1    Noyan-Ashraf, M.H.2    Hoefer, J.3    Bolz, S.-S.4    Drucker, D.J.5    Husain, M.6
  • 45
    • 84862521094 scopus 로고    scopus 로고
    • Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety
    • COI: 1:CAS:528:DC%2BC38Xjs1SjsrY%3D, PID: 22246377, Another more recent randomized, double-blinded crossover trial of 20 patients gives reason for caution regarding use of intravenous exenatide in patients with diabetes and HF. Although there was a significant reduction in pulmonary capillary wedge pressure during exenatide infusion, the observed improvement in cardiac index was secondary to a marked elevation in heart rate – by 21 ± 5 (29 %) bpm after 6 hours of exenatide infusion – rather than augmentation of stroke volum
    • Nathanson D, Ullman B, Löfström U, Hedman A, Frick M, Sjöholm A, et al. Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety. Diabetologia. 2012;55(4):926–35. Another more recent randomized, double-blinded crossover trial of 20 patients gives reason for caution regarding use of intravenous exenatide in patients with diabetes and HF. Although there was a significant reduction in pulmonary capillary wedge pressure during exenatide infusion, the observed improvement in cardiac index was secondary to a marked elevation in heart rate – by 21 ± 5 (29 %) bpm after 6 hours of exenatide infusion – rather than augmentation of stroke volume.
    • (2012) Diabetologia , vol.55 , Issue.4 , pp. 926-935
    • Nathanson, D.1    Ullman, B.2    Löfström, U.3    Hedman, A.4    Frick, M.5    Sjöholm, A.6
  • 46
    • 0032511583 scopus 로고    scopus 로고
    • Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
    • UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–53.
    • (1998) Lancet , vol.352 , Issue.9131 , pp. 837-853
    • UK Prospective Diabetes Study (UKPDS) Group1
  • 47
    • 65649106228 scopus 로고    scopus 로고
    • Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials
    • COI: 1:CAS:528:DC%2BD1MXmtleksbc%3D, PID: 1946523
    • Ray KK, Seshasai SRK, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373(9677):1765–72.
    • (2009) Lancet , vol.373 , Issue.9677 , pp. 1765-1772
    • Ray, K.K.1    Seshasai, S.R.K.2    Wijesuriya, S.3    Sivakumaran, R.4    Nethercott, S.5    Preiss, D.6
  • 48
    • 34250212715 scopus 로고    scopus 로고
    • Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
    • COI: 1:CAS:528:DC%2BD2sXms1SisrY%3D, PID: 1751785
    • Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457–71.
    • (2007) N Engl J Med , vol.356 , Issue.24 , pp. 2457-2471
    • Nissen, S.E.1    Wolski, K.2
  • 49
    • 77950903574 scopus 로고    scopus 로고
    • Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation
    • PID: 2041304
    • Kaul S, Bolger AF, Herrington D, Giugliano RP, Eckel RH. Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation. J Am Coll Cardiol. 2010;55(17):1885–94.
    • (2010) J Am Coll Cardiol , vol.55 , Issue.17 , pp. 1885-1894
    • Kaul, S.1    Bolger, A.F.2    Herrington, D.3    Giugliano, R.P.4    Eckel, R.H.5
  • 50
    • 53749096863 scopus 로고    scopus 로고
    • 10-year follow-up of intensive glucose control in type 2 diabetes
    • COI: 1:CAS:528:DC%2BD1cXht1Wgt7nK, PID: 1878409
    • Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–89.
    • (2008) N Engl J Med , vol.359 , Issue.15 , pp. 1577-1589
    • Holman, R.R.1    Paul, S.K.2    Bethel, M.A.3    Matthews, D.R.4    Neil, H.A.W.5
  • 51
    • 38549162147 scopus 로고    scopus 로고
    • Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years
    • COI: 1:CAS:528:DC%2BD1cXhvVOgtLs%3D, PID: 1805332
    • Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008;24(1):275–86.
    • (2008) Curr Med Res Opin , vol.24 , Issue.1 , pp. 275-286
    • Klonoff, D.C.1    Buse, J.B.2    Nielsen, L.L.3    Guan, X.4    Bowlus, C.L.5    Holcombe, J.H.6
  • 52
    • 77956654077 scopus 로고    scopus 로고
    • Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database
    • COI: 1:CAS:528:DC%2BC3cXhtFahs7jJ, PID: 2046044
    • Horton ES, Silberman C, Davis KL, Berria R. Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database. Diabetes Care. 2010;33(8):1759–65.
    • (2010) Diabetes Care , vol.33 , Issue.8 , pp. 1759-1765
    • Horton, E.S.1    Silberman, C.2    Davis, K.L.3    Berria, R.4
  • 53
    • 77958184434 scopus 로고    scopus 로고
    • Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition
    • COI: 1:CAS:528:DC%2BC3cXhtFahs7jO, PID: 2042421
    • Bunck MC, Diamant M, Eliasson B, Cornér A, Shaginian RM, Heine RJ, et al. Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care. 2010;33(8):1734–7.
    • (2010) Diabetes Care , vol.33 , Issue.8 , pp. 1734-1737
    • Bunck, M.C.1    Diamant, M.2    Eliasson, B.3    Cornér, A.4    Shaginian, R.M.5    Heine, R.J.6
  • 54
    • 84873554686 scopus 로고    scopus 로고
    • Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis
    • PID: 2335566
    • Robinson LE, Holt TA, Rees K, Randeva HS, O'Hare JP. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open. 2013;3(1):e001986–6.
    • (2013) BMJ Open , vol.3 , Issue.1 , pp. e001986-e1986
    • Robinson, L.E.1    Holt, T.A.2    Rees, K.3    Randeva, H.S.4    O'Hare, J.P.5
  • 55
    • 79951702236 scopus 로고    scopus 로고
    • Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the lifelink database
    • PID: 2092999
    • Best JH, Hoogwerf BJ, Herman WH, Pelletier EM, Smith DB, Wenten M, et al. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the lifelink database. Diabetes Care. 2010;34(1):90–5.
    • (2010) Diabetes Care , vol.34 , Issue.1 , pp. 90-95
    • Best, J.H.1    Hoogwerf, B.J.2    Herman, W.H.3    Pelletier, E.M.4    Smith, D.B.5    Wenten, M.6
  • 56
    • 84876983059 scopus 로고    scopus 로고
    • Longer acting GLP-1 receptor agonists and the potential for improved cardiovascular outcomes: a review of current literature
    • COI: 1:CAS:528:DC%2BC3sXms1GktLg%3
    • Tibble CA, Cavaiola TS, Henry RR. Longer acting GLP-1 receptor agonists and the potential for improved cardiovascular outcomes: a review of current literature. Expert Rev Endocrinol Metab. 2013;8(3):247–59.
    • (2013) Expert Rev Endocrinol Metab , vol.8 , Issue.3 , pp. 247-259
    • Tibble, C.A.1    Cavaiola, T.S.2    Henry, R.R.3
  • 57
    • 84865492997 scopus 로고    scopus 로고
    • Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus
    • COI: 1:CAS:528:DC%2BC38XovVagtb4%3D, PID: 2270386
    • Patil HR, Badarin Al FJ, Shami Al HA, Bhatti SK, Lavie CJ, Bell DSH, et al. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus. Am J Cardiol. 2012;110(6):826–33.
    • (2012) Am J Cardiol , vol.110 , Issue.6 , pp. 826-833
    • Patil, H.R.1    Badarin Al, F.J.2    Shami Al, H.A.3    Bhatti, S.K.4    Lavie, C.J.5    Bell, D.S.H.6
  • 58
    • 84883765959 scopus 로고    scopus 로고
    • Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
    • COI: 1:CAS:528:DC%2BC3sXhsF2ksbzN, PID: 2399260
    • Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–26.
    • (2013) N Engl J Med , vol.369 , Issue.14 , pp. 1317-1326
    • Scirica, B.M.1    Bhatt, D.L.2    Braunwald, E.3    Steg, P.G.4    Davidson, J.5    Hirshberg, B.6
  • 59
    • 84879460508 scopus 로고    scopus 로고
    • Incretins as a novel therapeutic strategy in patients with diabetes and heart failure
    • COI: 1:CAS:528:DC%2BC3sXjvFeqt7s%3D, PID: 2257010
    • Khan MA, Deaton C, Rutter MK, Neyses L, Mamas MA. Incretins as a novel therapeutic strategy in patients with diabetes and heart failure. Heart Fail Rev. 2013;18(2):141–8.
    • (2013) Heart Fail Rev , vol.18 , Issue.2 , pp. 141-148
    • Khan, M.A.1    Deaton, C.2    Rutter, M.K.3    Neyses, L.4    Mamas, M.A.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.